The FDA's Understanding And Application Of The APPH Standard in The JUUL Case

JUUL Labs, as a leading company in the e-cigarette industry, experienced multiple setbacks during its application for PMTA approval. This reflects the strict review mechanism of the FDA centered on "Protecting the Public Health" (APPH), which focuses on weighing the benefits of the product in reducing harm to adult smokers and the risk of addiction for teenagers. On July 30, 2020, JUUL submitted its PMTA application (including devices and 3%/5% concentration tobacco-flavored and peppermint-flavored pods), which centered on the two core considerations of the APPH standard: on the one hand, over 110 scientific studies (including a two-year longitudinal study) proved that the product could significantly facilitate the transition of adult smokers from combustible cigarettes; on the other hand, behavioral research and data on youth prevention measures (with the usage rate of minors dropping by over 98% since 2019) supported its low appeal to teenagers. Real-world evidence (RWE) further verified that the benefits of JUUL products outweighed the risks, including the conversion from smoking to e-cigarettes, reduction in cigarette consumption, and changes in dependence levels.
However, on June 23, 2022, the FDA issued a marketing denial order (MDOs) due to insufficient toxicological data, concerns over chemical leaching and genotoxicity. JUUL immediately received an administrative stay on July 5, 2022, allowing the product to remain on the market during further review, and submitted a supervision appeal on July 29. Subsequently, JUUL submitted supplementary documents for tobacco-flavored pods and the new generation of vaping platforms (tobacco-flavored and peppermint-flavored pods) on December 2022, July 19, 2023, and December 2023. On June 6, 2024, the FDA officially revoked the 2022 MDOs and resumed the substantive assessment. Finally, on July 17, 2025, the FDA granted marketing authorization for five products: JUUL devices, Virginia tobacco-flavored JUUL pods (3% and 5% nicotine concentration), and peppermint-flavored JUUL pods (3% and 5% nicotine concentration). This approval was based on the products meeting the APPH standard, that is, the benefits of the product in helping adult smokers achieve a complete conversion or significant reduction in harm outweighed the risks to teenagers. This lengthy review process established the extremely high standards of PMTA for applicants regarding the integrity of the scientific evidence chain, especially real-world evidence.
1. Overview of 39 Approved Products
As of the third quarter of 2025, there were 39 authorized electronic nicotine delivery systems (ENDS) products. This number alone is highly persuasive in demonstrating the strictness of the APPH standard application in the PMTA review. In stark contrast to the thousands of brands and flavored products available on the illegal market, the product variety in the legal market is extremely limited, strictly limited to tobacco and peppermint flavors. This reflects the balance between the conversion needs of adult smokers and the risk of preventing teenage smoking, prioritizing public health and holding an extremely cautious attitude towards flavored e-cigarettes that may attract teenagers.
The four major players in the legal market are JUUL Labs, R.J. Reynolds under British American Tobacco (Vuse brand), Oceania Group's NJOY, and Japan Tobacco International's Logic. (See Table 1) The approved entities generally have strong research, compliance, and long-term investment capabilities. This phenomenon indicates that PMTA is not a simple administrative licensing procedure but a regulatory mechanism centered on systematic scientific evidence and setting extremely high requirements for the comprehensive compliance capabilities of enterprises. Table 1: List of FDA-authorized electronic nicotine delivery system products (as of November 2025) Company product details (product name; flavor; device type; nicotine concentration) Logic Technology Development LLC - Logic Regular Cartridge/Capsule; Tobacco; Vape Pen - Logic Pro Capsule Tank System (1); Tobacco; Tank System - Logic Vapeleaf Cartridge/Capsule Package; Tobacco; Vape Pen - Logic Pro Capsule Tank System (2); Tobacco; Tank System - Logic Vapeleaf Tobacco Vapor System; Tobacco; Vapor System - Logic Power Tobacco e-Liquid Package; Tobacco; E-Liquid - Logic Pro Tobacco e-Liquid Package; Tobacco; E-Liquid - Logic Power Rechargeable Kit; Tobacco; Rechargeable Kit NJOY LLC - NJOY DAILY Rich Tobacco 4.5%; Rich Tobacco; Disposable; 4.5% - NJOY ACE POD Classic Tobacco 2.4%; Classic Tobacco; Vape Pen; 2.4% - NJOY DAILY EXTRA Rich Tobacco 6%; Rich Tobacco; Disposable; 6% - NJOY ACE POD Classic Tobacco 5% ; Classic tobacco ; Smoke cartridge 5% - NJOY DAILY EXTRA Menthol 6% ; Mint ; One-time use 6% - NJOY ACE POD Rich Tobacco 5% ; Strong tobacco; cigarette cartridge; 5% - NJOY DAILY Menthol 4.5%; mint; disposable; 4.5% - NJOY ACE POD Menthol 2.4%; mint; cartridge; 2.4% - NJOY ACE Device; device - NJOY ACE POD Menthol 5%; mint; cartridge 5%R.J. Reynolds Vapor Company- Vuse Vibe Power Unit (1) ; Power Unit - Vuse Replacement Cartridge Original 4.8% G2; Original Flavor; Smoke Bullet; 4.8% - Vuse Vibe Tank Original 3.0%; Original Flavor; Tank; 3.0% - Vuse Alto Power Unit; Power Unit - Vuse Vibe Power Unit (2); Power Unit - Vuse Alto Pod Golden Tobacco 5%; Golden Tobacco; Smoke Bullet; 5%- Vuse Ciro Power Unit (1) ; Power Unit - Vuse Alto Pod Rich Tobacco 5%; Rich Tobacco; Smoke Pen; 5% - Vuse Ciro Cartridge Original 1.5%; Original Flavor; Smoke Pen; 1.5% - Vuse Alto Pod Golden Tobacco 2.4%; Golden Tobacco; Smoke Pen; 2.4% - Vuse Ciro Power Unit (2); Power Unit - Vuse Alto Pod Golden Tobacco 1.8%; Golden Tobacco; Smoke Pen; 1.8% - Vuse Replacement Cartridge Original 4.8% G1; Original Flavor; Smoke Pen; 4.8% - Vuse Alto Pod Rich Tobacco 1.8%; Rich Tobacco; Smoke Pen; 1.8% - Vuse Solo Power Unit; Power Unit - Vuse Solo Original Cartridges 4.8%; Original Flavor; Smoke Pen; 4.8% JUUL Labs Inc. - JUUL Device; Device - Virginia Tobacco JUULpod 3%; Virginia Tobacco; Smoke Pen; 3% - Virginia Tobacco JUULpod 5% ; Virginia tobacco ; cigarette cartridge 5% - Menthol JUULpod 3% ; Mint ; Smoke bomb 3% - Menthol JUULpod 5% ; Mint ; Smoke bomb 5%
II. The Core of Legal Review: The Connotation of the APPH Standard and the Balance
The core of the PMTA review is the "Appropriate for the Protection of Public Health" (APPH) standard stipulated in the "Tobacco Control Act" of 2009 of the United States. Article 910(c)(4) of the Tobacco Control Act requires that before any new tobacco product is marketed in the United States, the FDA must prove that its marketing will "be appropriate for the protection of public health". When judging whether a product meets this standard, the FDA must weigh the risks and benefits to the entire population (risks and benefits to the population as a whole) and consider the following two possibilities and their variations: 1) the possibility that existing tobacco users will quit tobacco use; 2) the possibility that non-tobacco-using individuals (including teenagers) will start using tobacco products.
A case that demonstrates how the FDA conducts public health reviews is Avail Vapor, LLC v. FDA. In this case, Avail Vapor claimed that its electronic cigarette products could provide a lower-risk nicotine intake pathway for adult smokers, and therefore should meet the APPH standard. However, the FDA pointed out in the review that Avail's submitted documents failed to fully prove that adult smokers would significantly reduce their use of traditional cigarettes due to this product, and there was a lack of sufficient data to show that the product would not attract non-smoking teenagers to try nicotine. The court supported the FDA's approach in the judgment, but at the same time emphasized that when applying the APPH standard, the FDA must openly and transparently weigh the potential impacts of the product on different populations - including the social benefits for adult smokers in reducing harm and the social risks brought about by teenagers starting to use tobacco products and becoming addicted. In other words, the FDA must clearly explain at the evidence level how it believes the benefits do not outweigh the potential risks, and cannot simply reject the product on the grounds that the risk to teenagers has increased.
Therefore, the FDA's assessment is not to pursue an idealized product with zero risks, but to conduct a risk-benefit balance based on the overall population's health. On one end of the scale, the potential benefits of the product for existing adult tobacco users - that is, helping them completely switch or significantly reduce the consumption of more harmful traditional cigarettes. On the other end of the scale, the risks that the product may bring to non-tobacco users, especially the teenage group - that is, inducing them to start using nicotine products and becoming addicted. During the application of the APPH standard, the FDA does not avoid the existing or potential risks that the product may have in the teenage group, but requires the applicant to provide specific and verifiable evidence to prove that the public health benefits brought by the overall market entry outweigh the risks.

III. Main Application Process and Core Document Composition of PMTA
Stages Key Steps and Milestones Core Documents Specific Composition and Key Data Requirements FDA Review Focus 1. Pre-Submission
(Product Characterization and Tobacco Product Master File (TPMF) Construction) Product Master List (Master SKU List), Authorization Letter (LOA) • SKU Definition: Clearly define nicotine concentration, flavoring, packaging specifications.
• Authorization Letter Content: Must include the name of the TPFM holder, TPFM number, specific product range and date. Strategy Warning: If there is no LOA, the applicant must submit all detailed confidential information on the formulation and manufacturing process on their own, which is usually not feasible. Pre-Submission Meeting Briefing Package • Proposed Test Plan (Toxicology/Clinical), Specific Scientific Issues, Product Manual. Use this opportunity to confirm the availability of data and avoid doing useless work later. 2. Compilation
(Administrative Information Module Construction) FDA Form 4057 (Application Form), FDA Form 4057b • 4057: Detailed contact information of the applicant/agent.
• 4057b: Precisely list the attributes of each product (flavor, nicotine type, etc.), used for system grouping. Electronic Format: All files must comply with e-Submitter standards, file names must not contain special characters, and must have a complete hyperlink index. Label and Marketing Plan Label Sample (Labeling), Marketing Limitation Plan (Marketing Plan) • Label: Nicotine warning text (30% of the page), ingredient list, batch number tracking code.
• Marketing Plan: Detailed description of measures to restrict teenagers (such as age verification technology, social media restriction commitment). Prohibition of suggesting that the product has therapeutic effects or is safer than cigarettes. Marketing Materials Must Not Include Cartoon Images or Elements Targeted at Teenagers. Environmental Assessment (EA) Environmental Assessment Report • Directory Structure: Affected environment, air/water resource impact, waste disposal, environmental justice.
• Confidential Version and Public Version: Two versions must be provided. Direct Rejection (Refuse to Accept, RTA) Risk: If EA is missing or incorrect classification exclusion statements are provided, it will be directly rejected at the acceptance stage. Manufacturing and Quality Main Manufacturing Records, Batch Production Records • Main Manufacturing Records: Detailed process flow diagram, equipment parameters, key control points.
• Batch Production Records: Records of actual production batches, proving compliance with the main manufacturing records. Consistency: Must prove that the commercial production products are of the same quality as the samples submitted to FDA for testing. Scientific Module: Chemical/Toxicology Aerosol Harmful Components (HPHC) Test Report, Toxicology Evaluation Report • HPHC: Data and methodological validation for 33 components of e-cigarettes (formaldehyde, heavy metals, etc.).
• Toxicology: In vitro experiments including Ames test (OECD 471, assessing mutagenicity), neutral red uptake test (assessing cytotoxicity), micronucleus test (OECD 487, assessing genetic toxicity), QSAR (Quantitative Structure-Activity Relationship) model data. If only testing the e-liquid but not covering the full life cycle data of the aerosol, it will be difficult to meet the PMTA's requirements for evaluating the real usage state of the product. Scientific Module: Behavioral Perception and Intent Study (TPPI), Bridging Memo (Bridging Memo) • TPPI: Data on the intent of non-users/teenagers.
• Bridging: Demonstrate how the existing literature data can be applied to this product. The fatal flaw of the "Request for Denial" (MDO): For flavored products, if there is a lack of specific data proving that their benefits for adults are greater than the risks for teenagers, it is highly likely to be rejected. 3. Submission and Review
(Review Process) Submit (Submission) upload the complete compressed file package to the FDA Tobacco Products Center • Through the FDA portal upload the complete compressed file package. Timestamp: Based on the time of receipt by the FDA server. Acceptance (Acceptance Letter) or Refusal to Accept Letter (RTA) • Check items: completeness of the form, existence of EA, validity of TPMF citation, and compliance with electronic format. Rejection at this stage requires a complete reattempt without refund (if applicable). Common errors: outdated form version, file encryption. Filing Review (Filing) Filing Letter or Refusal to File Letter (RTF) • Check items: completeness of scientific data. Including but not limited to whether there is HPHC data? Whether there are stability data? This is the ticket to enter the substantive review. If the core module is missing (such as no toxicological data), the filing will be rejected. Substantive Review (Deficiency Letter) • Feedback mechanism: The FDA lists specific scientific questions (such as "Explain the reasons for excessive formaldehyde"). • Response: The applicant needs to submit supplementary data within the specified time frame (90-180 days). During the period of major defect response, the 180-day review cycle may be suspended. This is the last chance to save the application. 4. Decision
(Decision) Regulatory action Market Access Order (MGO) • Includes specific post-market obligations (reporting, record keeping). Maintenance: Reports need to be submitted quarterly/annually. Market Denial Order (MDO) • Includes detailed scientific/legal reasons for rejection. Consequences: The product must be removed from the market. Administrative reconsideration or litigation can be applied for.
III. Conclusion
In summary, the PMTA system conducts a systematic weighing of risks and benefits at the population level in the United States based on the APPH standards. The FDA does not aim for a zero-risk product, but rather to maximize the net public health benefit under controllable risks. This system design determines the high concentration of evidence standards, research depth, and compliance costs in the PMTA review, which also explains why the number of products that pass the review remains at an extremely low level.